Honest answer: most people feel essentially nothing acutely from leucine. It's not psychoactive. It doesn't produce pump, focus, or mood. The anabolic effect is subcellular and the timeline is 1-3 hours post-dose. What users report:

• Slight palatability issue — free-form leucine powder is notably bitter. Capsules avoid this but pill-burden goes up because 5 g = ~10 large capsules.
• Minor GI rumble at higher doses (10 g+) — taking it on empty stomach can produce mild bloating or quick stool urgency in sensitive users. Splitting the dose or taking with food eliminates this.
• Mild insulin response — fasting users may notice slight transient drowsiness or post-meal-like calm at 5 g on empty stomach. Disappears with food.
• Subjective recovery / DOMS reduction — some users report less next-day soreness when adding 2.5-5 g leucine post-training. The 2024 BCAA overview (Salem PMID 38241335) supports a small CK-attenuation and DOMS effect, so this isn't pure placebo.
• No stimulant effects — leucine isn't classified as a stim under any reasonable definition. No HR, BP, or sympathetic effect.

Honest variability: ~80%+ of users describe leucine as "I can't tell I'm taking it." The 10-15% who report DOMS reduction are likely real responders. The remainder report bloat or pill burden as the main subjective notes.

• No meaningful tolerance. Leucine works on a stoichiometric trigger model — Sestrin2 binds it, dissociates from GATOR2, mTORC1 activates. There's no receptor downregulation paradigm here. The "diminishing returns" effect comes from the leucine threshold itself: once mTORC1 is saturated in a given meal, more leucine does nothing in that window. The next meal resets the system.
• No cycling needed for typical daily supplementation at dietary-range doses (2-10 g/day).
• Dose-titration consideration: If using as a per-meal rescue protocol, you don't need to escalate. 2-3 g rescues a sub-threshold meal indefinitely.

Synergistic / complementary

• Whey protein — Whey already delivers 2.5-3 g leucine per 25 g scoop, so adding free leucine to a whey shake is generally redundant. The exception: very low-dose whey (10-15 g/serving, e.g., a half-scoop in a smaller meal) plus 2 g leucine top-up reproduces the Devries 2018 protocol — lower-protein, leucine-enriched serving that matches a full whey dose.
• Full EAA blend — Full EAA powders (containing all 9 essential amino acids in physiologic ratios) cover both the leucine trigger and the sustained-MPS tail. Better than isolated BCAA or leucine for fasted-state use.
• Creatine monohydrate — Independent mechanism (PCr buffering, cell volumization, IGF-1 expression). Creatine + leucine + whey is the rare stack where each component has a non-overlapping rationale.
• Casein pre-bed — Casein already supplies leucine over hours. Free leucine isn't a clean add — go with casein alone.
• HMB (3 g/day) — The leucine metabolite. Worth considering as a separate compound especially during energy restriction or anti-catabolic phases; see hmb.md for the full breakdown.
• Carbohydrate + leucine post-workout — Insulinogenic stack; carbs amplify leucine's modest insulin response and improve nutrient delivery to muscle.

Avoid stacking with

• Isolated BCAAs (leucine + iso + valine in 2:1:1) when you're already taking standalone leucine — you're paying for the same leucine twice, plus iso/valine that may compete for transport.
• Tryptophan or 5-HTP near sleep onset if you're sensitive to leucine's competition for BBB LAT1 transport — large neutral amino acids compete; leucine pre-bed could (theoretically) blunt nocturnal tryptophan → serotonin → melatonin conversion. Anecdotal, but if you're already on 5-HTP or trazodone-style sleep aids, dose leucine earlier in the day.

Neutral

• Most V4 stack items (mag, NAC, citicoline, PS, DHA, curcumin, rhodiola, theanine, glycine, D3/K2, beta-alanine, vitamin C) — no relevant interactions.
• Modafinil, peptides, other planned V5 items — no relevant interactions.

Leucine has minimal clinically significant drug interactions in healthy users. Notable cases:

• Levodopa (Parkinson's treatment): Large neutral amino acids (including leucine) compete with levodopa for the LAT1 transporter at the gut and BBB. High-protein meals reduce levodopa absorption and CNS bioavailability. Patients on levodopa should time protein meals 2+ hours away from levodopa dosing. Not relevant to Dylan; flagged for completeness.
• Hypoglycemic agents: Theoretically additive insulin effect with metformin, sulfonylureas, insulin therapy. Effect size is small; clinically not a real issue at typical leucine doses.
• Diuretics: No interaction.
• Statins: No clinically relevant interaction documented for leucine specifically; statin-induced myopathy and BCAA metabolism are independent concerns.
• MAOIs / SSRIs: No clinically relevant interaction.
• Lithium: No interaction.
• Cancer chemotherapy: Leucine drives mTORC1 — theoretically antagonistic to mTOR-inhibitor regimens (everolimus, sirolimus) and possibly proliferative for some tumor types. Clinical relevance limited; oncology guidance overrides general supplement advice during active treatment.

Pharmacokinetic interactions:

• Free leucine is absorbed rapidly via sodium-dependent neutral amino acid transporters in the small intestine. Bioavailability is essentially complete.
• First-pass hepatic extraction is low for leucine specifically (unlike most amino acids where the liver extracts a large fraction); leucine reaches systemic circulation efficiently.
• No CYP450 involvement. No protein-binding displacement of other drugs.

Leucine PGx data is sparse compared to drug-metabolism PGx because leucine isn't metabolized by CYPs and the relevant variants sit in pathway components rather than detox enzymes.

• BCKDH variants — Severe loss-of-function causes Maple Syrup Urine Disease (MSUD). Carrier (heterozygous) variants may produce subtly slower BCAA oxidation but no clinically meaningful supplementation guidance.
• Sestrin2 (SESN2) variants — Population-level common variants exist but functional consequence on leucine sensing in adult humans is not well characterized.
• mTORC1 pathway variants (RAGA, RAGC, RHEB, MTOR, RPTOR) — Most are highly conserved; loss-of-function variants typically catastrophic and rare.
• Insulin receptor / IRS-1 / S6K1 variants — These sit downstream of leucine signaling and may modulate the interaction between BCAA intake and insulin sensitivity. The clinical translation isn't actionable yet.
• 23andMe relevance for Dylan: Once his 23andMe results land (June 2026), the most useful loci to interrogate are BCKDH (MSUD carrier risk — almost certainly negative) and any insulin-resistance polygenic risk markers that might escalate caution on chronic high-dose BCAA loading. None of this would change the basic verdict: skip standalone leucine while protein intake is adequate.

For Dylan specifically: No purchase recommended. V4 whey + dietary animal protein already saturates the leucine threshold 4-5x daily. If he ever wants to experiment with the rescue protocol on a plant-heavy day, a 500 g bag of Nutricost L-leucine ($15-20) lasts months.

Baseline (before starting, if you decide to use it)

• Total daily protein intake (g/kg/day) — log a 3-day food diary. If you're already at 1.6+ g/kg from animal sources, that's your answer: leucine supplementation adds nothing.
• Lean body mass (DEXA, BIA, or simple body-comp tracking) — establishes baseline for any LBM-preservation trial.
• Fasting insulin + HOMA-IR — relevant if you're loading chronic high-dose BCAAs and want to detect any IR drift over months.
• ALT/AST (liver) — covered in Dylan's June 2026 panel. Leucine has no hepatotoxicity at typical doses but liver disease is a contraindication for self-supplementation.
• Plasma BCAAs (research lab; not typically clinical) — useful if running a formal experiment. Most users skip this.

During use

• DOMS / recovery subjective rating — daily 1-10 scale post-training. The 2024 BCAA overview suggests a small effect on CK and soreness; if you don't notice anything subjective over 4-6 weeks, the marginal benefit is probably not worth the slot.
• LBM monthly — DEXA or BIA if you have access; otherwise mirror + scale + lift progression.
• GI tolerance — any bloat / loose stool that persists is a signal to lower dose or stop.

Long-term

• Fasting glucose + HbA1c annually — chronic high BCAA intake is associated with insulin resistance in observational studies. In lean trained athletes the association is weak, but worth tracking.
• Resting heart rate / Oura recovery scores — no direct leucine signal but useful for overall training-load tracking; tells you whether the broader stack is helping or not.